Speaking of Urology: ASCO GU 2023 Highlights - Apple Podcasts Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 26 in Chicago. 2023 ASCO GI Cancers Symposium arrow_drop_down Starts at 7:00 AM PST, Jan 19 - Jan 21, 2023 In-Person & Online | San Francisco, CA Thu 19 Fri 20 Sat 21 calendar_today Scheduled Sessions event_available My Agenda ondemand_video On Demand note Posters menu More grid_view Calendar View download Export to Calendar We report extended follow-up data. Memorial Sloan Kettering Cancer Center at ASCO 2023 Care Delivery and Regulatory Policy. . The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Six months of a GnRH agonist with SRT is a standard of care for patients with unfavorable features and a detectable PSA post-RP. Clinical pathways utilization and characteristics - ASCO Publications More than 130 abstracts will feature 22 approved and potential new medicines across the Company's diverse oncology . Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy. Multidisciplinary Thoracic Cancers Symposium, AACR/ASCO Methods in Clinical Cancer Research Workshop, Combined Hematology/Oncology and Hospice & Palliative Medicine Training, Quality Oncology Practice Initiative (QOPI), Patient-Centered Standards for Medically Integrated Dispensing, Standards for Safe Handling of Hazardous Drugs, Policies for Volunteers & Committee Members, 2023 ASCO GU Cancers Symposium - Oral Abstract Session. Dates to Know | ASCO Genitourinary Cancers Symposium Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation. Learn about a clinical trial at Memorial Sloan Kettering that gives people with rectal cancer a new option to be treated without radiation. If you are not an ASCO member, you can create a guest account. Check back here throughout the meeting for the latest updates, presentation highlights, news releases, and award recipients. 4502 Oral Abstract Session Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell Ready to start planning your care? Our highly-specialized educational programs shape leaders to be at the forefront of cancer care and research. Interim data showed improved OS with Arm A vs C but did not cross the pre-specified threshold for significance (Galsky Lancet 2020; Galsky AACR 2021). Integrating Genomic Profiling in the Care of Patients with Sarcoma: From Diagnosis to Therapy, Organizational Strategies to Promote Professional Wellness, Perspective on Incidence and Management of Neurotoxicity. A subset of these encounters, those ordered without use of Elsevier's ClinPath, "pathway-independent," were . Subscribe today! Visit Site A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004. The 2 primary endpoints of the CheckMate 274 trial were met as nivolumab (NIVO) improved disease-free survival (DFS) versus placebo (PBO) in the intent-to-treat (ITT) population and in patients with tumor programmed death ligand 1 (PD-L1) expression 1%. The TRISST randomized trial (NCT00589537) demonstrated that effective monitoring could be achieved with a reduced scan schedule or using Magnetic Resonance Imaging (MRI) instead of CT. Guest host Dr. Neeraj Agarwal and Dr. Christian Kollmannsberger discuss practice-changing abstracts that were presented at the 2023 ASCO Genitourinary Cancers Symposium, including results from the TALAPRO-2, PROpel, TRITON3, ARASENS, KEYNOTE-057, CheckMate 274, and CheckMate 9ER studies. First-line nivolumab plus cabozantinib (N+C) demonstrated superiority over sunitinib (S) with 25.4 mo minimum follow-up (median, 32.9 mo) in patients (pts) with aRCC in the CheckMate 9ER trial. If you are not an ASCO member, you can create a guest account. A phase II study of olaparib (AZD2281) in patients (Pts) with Session: Poster Session, Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancerDate/Time: Sunday, June 4, 8:00 a.m. (CDT), Presenter: Natlia PolidorioSession: Poster Session, Do HER2 low tumors have a distinct clinicopathologic phenotype? . Poster Presenter Guidelines | Oncology Meetings Do HER2 low tumors have a distinct clinicopathologic phenotype? The ZIRCON study evaluated the performance of TLX250-CDx PET/CT for detection of ccRCC in adult patients with indeterminate renal masses (IDRM). For live updates from @MSKCancerCenter on the ground in Chicago or to join the conversation when posting from your feed, use the hashtag #ASCO23 on Twitter andLinkedin. Ingo Mellinghoff, MD, FACP: Plenary Presentation, A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Date/Time: Sunday, June 4, 1:05 p.m. CDT, Deb Schrag, MD, MPH: Plenary Presentation, A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)Date/Time: Sunday, June 4, 1:41 p.m. CDT, Presenter: Michael Francis Walsh, MDSession: Clinical Science Symposium, POT1 germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition.Date/Time: Sunday, June 4, 5:06 p.m. CDTPresenter: Zsofia Kinga Stadler, MDSession: Redefining early-onset cancer and risk of hereditary cancer predispositionDate/Time: Sunday, June 4, 4:42 p.m. CDT, Presenter: Alexander Drilon, MDSession: Poster Discussion Session, A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.Date/Time: Saturday, June 3, 1:15-2:45 p.m. CDT, On Demand, Presenter: Gregory Riely, MD, PhDSession: Poster Discussion Session, Efficacy, and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Date/Time: Sunday, June 4, 4:30-7:00 p.m. CDT, Presenter: Megha Ranganathan, MS, CGCSession: Case-Based Panel, Managing Cancer Risk in Transgender Patients With Inherited Cancer PredispositionDate/Time: Sunday, June 4, 11:30 a.m. CDT, Presenter: Fumiko Chino, MDSession: Oral Abstract Session, Threading the Needle of Patient Access and Provider Well-BeingDate/Time: Saturday, June 3, 2:51 p.m. CDT, Presenter: Alicia Latham, MD, MSSession: Education Session, Early-Onset Cancer and Genetic Predisposition: Knowns and UnknownsDate/Time: Saturday, June 3, 1:55 p.m. CDT, Presenter: Deb Schrag, MD, MPHSession: Special Sessions, ASCO-ACS Cancer Prevention Award LectureDate/Time: Friday, June 2, 12:00 p.m. (CDT), Presenter: Mark Andrew Dickson, MDSession: Case-Based Panel, Navigating Retroperitoneal Sarcoma: Twists, Turns, and Challenges AheadDate/Time: Friday, June 2, 4:45 p.m. (CDT), Presenter: David H. Ilson, MD, PhDSession: Oral Abstract Session, Is Timing Everything? ASCO is committed to transparency regarding our websites and the ways we process data. Program Guide - ASCO Meeting Program Guide Dates to Know | Oncology Meetings The IMvigor130 primary analysis demonstrated statistically significant PFS benefit with 1L atezo + plt/gem (Arm A) vs placebo + plt/gem (Arm C) in pts with mUC (Galsky Lancet 2020). ASCO GU 2022: The Effect of Postoperative Pathological - UroToday Abstract FAQs - Infectious Diseases Society of America Radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) is highly specific for CAIX and can aid differentiation between ccRCCs and other renal lesions. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. All Rights Reserved Worldwide. A new experimental drug could be an effective treatment for some people with low-grade glioma. Managing Cancer Risk in Transgender Patients With Inherited Cancer Predisposition, Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers, Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. ASCO Genitourinary Cancers Symposium: Featured Abstracts FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). Results from cohort A (carcinoma in situ [CIS] papillary tumors) showed a clinical complete response rate of 41% at 3 mo and led to approval of pembro monotherapy for such pts in the United States. ASCO-American Cancer Society Cancer Prevention Award, Members of the media interested in speaking with MSK experts, please contact:John Connolly Urothelial Cancer Highlights. Patient-level data meta-analysis of a multi-modal artificial intelligence (MMAI) prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG phase III randomized trials. Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer. Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Our scientists pursue every aspect of cancer researchfrom exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more. ASCO Meetings 2023 American Society of Clinical Oncology Genitourinary (ASCO GU The ASCO GU 2023 abstracts on urothelial cancer explore management of early-stage disease with biomarkers to detect minimal residual disease and immunotherapy for non-muscle invasive bladder cancer immunotherapy. Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6 in . Memorial Sloan Kettering Cancer Center (MSK) is proud to honor the work of our physician-scientists and researchers presenting at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6 in Chicago. Date/Time:Monday, June 5,8:00 a.m. (CDT), Presenter:Ghassan K. Abou-Alfa, MDSession:Poster Session, Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Date/Time:Monday, June 5,8:00 a.m. (CDT), Presenter:Lorenzo Falchi, MDSession:Poster Session, Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.Date/Time:Monday, June 5,8:00 a.m. (CDT), Presenter: Michael J. Morris, MDSession: Education Session, Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI perspectivesDate/Time: Monday, June 5, 11:30 a.m. (CDT), Presenter: Jessica Scott, PhDSession: Case-Based Panel, Cardiac Toxicity in Oncology: Prevention and Surveillance Strategies for Early and Late Effects of Treatment: The Exercise Physiologist PerspectiveDate/Time: Monday, June 5, 11:30 a.m. (CDT), Presenter: Sujana Movva, MDSession: Oral Abstract Session, Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohortDate/Time: Monday, June 5, 11:30 a.m. (CDT), Presenter: Robert J. Motzer, MDSession: Oral Abstract Session, Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trialDate/Time: Monday, June 5, 11:30 a.m. (CDT), Presenter: Helen Ajufo, MDSession: Poster Discussion Session, Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trialDate/Time: Monday, June 5, 11:30 a.m. (CDT), Presenter: Floris S. VerheijSession: Poster Discussion Session, Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trialDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Ryan M. Kahn, MD, MHSSession: Poster Session, Germline variants in non-BRCA1/2homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survivalDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Ying L Liu, MD, MPHSession: Poster Session, Pathogenic germline variants in patients with endometrial cancer across diverse ancestriesDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Antoine DesiletsSession: Poster Session, A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancerDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Maliheh Mohamadpour, MDSession: Poster Session, A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinomaDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Alan Loh Ho, MD, PhDSession: Poster Session, A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neckDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Brian H. Kushner, MDSession: Poster Session, Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapyDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Neeta Pandit-Taskar, MDSession: Poster Session, 8F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBGDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Lorenzo Falchi, MDSession: Poster Session, Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 dataDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Erin Mary Bange, MD, MSCESession: Poster Session, Are we ready to mitigate time toxicity of cancer care? Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. Here, we report the final OS analysis from IMvigor130 Arms B and C. Although most pts with HR NMIBC respond to BCG, pts whose cancer does not respond or who relapse within 12 mo have poor prognosis and require radical cystectomy (RC). Memorial Sloan Kettering Cancer CenterCon[emailprotected], Pursuing basic and translational research across 9 programs and 100+ labs, Focusing on clinical cancer research and population health, Bridging the lab and the clinic through translational research, Fostering interdisciplinary collaborations between laboratory scientists and clinicians, Partnering with other academic and research institutions, Offering state-of-the-art resources for our researchers, Offering a curriculum with a focus on cancer, Connecting college seniors to future careers in biomedicine, Memorial Sloan Kettering Cancer Center at ASCO 2023. In exploratory analyses, OS improved when atezo was combined with cisplatin (cis) vs carboplatin (carbo) regardless of PD-L1 status. Date/Time: Sunday, June 4, 4:30 p.m. (CDT), Presenter: Megha Ranganathan, MS, CGCSession: Case-Based Panel, Managing Cancer Risk in Transgender Patients With Inherited Cancer PredispositionDate/Time: Sunday, June 4, 11:30 a.m. (CDT), Presenter: Sarat Chandarlapaty, MD, PhDSession: Education Session, The Evolution of ADC DevelopmentDate/Time: Sunday, June 4, 4:30 p.m. (CDT), Presenter: Sara P. MyerSession: Poster Session, Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriersDate/Time: Sunday, June 4, 8:00 a.m. (CDT), Presenter: Sara P. Myer Call for Papers - confex.com ASCO Genitourinary Cancers Symposium - Cancer Network Call for Abstracts 2022 ASCO Annual Meeting (June 3 - June 7, 2022) Helpful Tips Before You Begin Your Submission: To submit an abstract, you will need to log in with an ASCO.org account. Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer. In addition to these studies, forthcoming press . 2318 Mill Road, Suite 800, Alexandria, VA 22314 | Phone 571-483-1300 | 2023 American Society of Clinical Oncology (ASCO) All Rights Reserved Worldwide Pts unselected for genetic alterations in DNA damage repair pathways, directly or indirectly involved with homologous recombination repair (HRR), received either TALA + ENZA or PBO + ENZA as 1L treatment for mCRPC. Ingo K. Mellinghoff, MD, FACP, neuro-oncologist and Chair of the Department of Neurology, presented significant results from a phase III trial in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. It was previously reported that rucaparib significantly improved the primary endpoint of radiographic progression-free survival (rPFS) vs physicians choice in pts with BRCA or ATM alterations. MD Anderson Research Highlights: ASCO 2023 Special Edition Here, we report final OS data from Arms A and C. Two interim OS analyses from IMvigor130 demonstrated non-statistically significant OS benefit with atezo monotherapy (Arm B) vs placebo + platinum (investigator [INV] choice of carboplatin or cisplatin [carbo or cis])/gemcitabine (plt/gem; Arm C) in patients (pts) with PD-L1high (IC2/3) mUC, as well as a favorable safety profile vs chemo (Galsky Lancet 2020, Davis AACR 2021). Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. What Is the Role of Allogeneic Stem Cell Transplant for Older Patients WithAcute Myeloid Leukemiain 2023? Call for Abstracts 2023 ASCO Genitourinary Cancers Symposium (February 16-18, 2023) Helpful Tips Before You Begin Your Submission: To submit an abstract, you will need to log in with an ASCO.org account. Program Guide - ASCO Meeting Program Guide Herein, we validated the MMAI biomarker in high-risk prostate cancer where an increasing number of therapeutic decisions is required. The Grants & Awards Ceremony and Reception is being held Friday, June 2, 2023 at 4:00 p.m. CST at the Hyatt Regency McCormick Place, Regency Ballroom. Innovative Solutions to the Challenges of Cancer Clinical Trials: FDA and NCI perspectives, Cardiac Toxicity in Oncology: Prevention and Surveillance Strategies for Early and Late Effects of Treatment: The Exercise Physiologist Perspective, Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort, Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial, Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial, Germline variants in non-BRCA1/2homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival, Pathogenic germline variants in patients with endometrial cancer across diverse ancestries, A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer, A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma, A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck, Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy, 8F-MFBG PET imaging in patients with neuroblastoma: Lesion targeting and comparison with MIBG, Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data, Are we ready to mitigate time toxicity of cancer care? Recently, an MMAI prognostic biomarker, ArteraAI Prostate, was trained and validated in localized prostate cancer to more accurately risk stratify patients for multiple endpoints compared to NCCN risk groups (Esteva et al., 2022). MSK researchers will share their work at more than 100 sessions, including two plenary sessions with work from Ingo Mellinghoff, MD, MPH, neuro-oncology, and Deb Schrag, MD, MPH, gastro-oncology. Call us at 833-347-1665 to make an appointment. ASCO GU 2023: Prostate & Urothelial Cancer Abstracts Highlights A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation. A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101. Abstracts Submission Guidelines & Requirements Key Dates Abstract Submission Deadline: October 11, 2022 at 11:59 PM (EDT) Late-Breaking Abstract Submission Deadline: December 13, 2022 at 12:00 PM (EST) Abstract Change/Withdrawal Deadline: January 5, 2023 at 12:00 PM (EST) Abstract Eligibility Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC). Redefining early-onset cancer and risk of hereditary cancer predisposition, POT1germline pathogenic variants and evolving understanding of tumor spectrum: Evidence for lung cancer predisposition, Efficacy, and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study, Advances in Diagnostics and Response Assessment for Leptomeningeal Disease. genitourinary (GU), and gastrointestinal (GI) chemotherapy encounters ordered from July 2020 through June 2021 were identified. Oncologists perceptions on digital interventions to fast-track cancer careDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Semanti MukherjeeSession: Poster Session, Association of smoking history extracted from electronic health records (EHR) using machine-learning methods and tumor characteristics in patients with lung cancerDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Sarah P. Suehnholz, PhDSession: Poster Session, Quantifying the growth of clinical actionability in precision oncology using OncoKBDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Robert Michael Daly, MD, MBASession: Poster Session, Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer CoalitionDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Victoria Susana Blinder, MDSession: Poster Session, Patient-reported usefulness of an intervention to promote job retention among women undergoing (neo)adjuvant breast cancer chemotherapyDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Fumiko Chino, MDSession: Poster Session, It was so many hoops to jump through: Patient-reported administrative burden from disability, Family and Medical Leave Act (FMLA), and insurance appealsDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Samyukta Mullangi, MD, MBDASession: Poster Session, Association of participation in Medicares Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysisDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Iris Zhi, MD, PhDSession: Poster Session, Association of participation in Medicares Oncology Care Model with spending, utilization, and quality outcomes among commercially insured and Medicare Advantage members: A national difference-in-differences analysisDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Sherry Shen, MDSession: Poster Session, Evaluation of a mobile behavior change program for weight loss in breast cancer survivors: A prospective single-arm pilot studyDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Kirin SaintSession: Poster Session, Impact of exercise on chemotherapy-induced peripheral neuropathy (CIPN) in survivors with post-treatment primary breast cancerDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Anthony Francis Yu, MD, MSSession: Poster Session, Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapyDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Jun J. Mao, MD, MSCESession: Poster Session, Acupuncture versus massage for pain in patients living with advanced cancer: The IMPACT randomized clinical trialDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Shari Beth Goldfarb, MDSession: Poster Session, Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopeciaDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Talya Salz, PhDSession: Poster Session, Experiences with pain management for survivors of complex cancers: Focus on opioids and cannabisDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Kirin SaintSession: Poster Session, A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatmentDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Ivana Lopez-NievesSession: Poster Session, A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy in survivors of cancerDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Jamie S. Ostroff, PhDSession: Poster Session, Empathic communication skills training: Randomized controlled trial to reduce lung cancer stigma in lung cancer careDate/Time: Monday, June 5, 1:15 p.m. (CDT), Presenter: Vijai Joseph, PhDSession: Oral Abstract Session, Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypesDate/Time: Monday, June 5, 3:00 p.m. (CDT), Presenter: Saad Zafar Usmani, MD, MBA, FACPSession: Poster Session, A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: An interim analysis of DREAMM-9Date/Time: Monday, June 5, 3:00 p.m. (CDT), Presenter: Lara Dunn, MDSession: Poster Session, Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)Date/Time: Monday, June 5, 4:00 p.m. (CDT), Presenter: Martinique OgleSession: Poster Session, Fertility post immune checkpoint blockadeDate/Time: Monday, June 5, 4:30 p.m. (CDT), Presenter: Shari Beth Goldfarb, MDSession: Poster Session, Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapyDate/Time: Monday, June 5, 4:30 p.m. (CDT), Presenter: Alexander E. DrilonSession: Highlights of the Day Session, Highlights of Developmental TherapeuticsMolecularly Targeted Agents and Tumor BiologyDate/Time: Tuesday, June 6, 8:00 a.m. (CDT).
Pashley Roadster For Sale, Grants For Oncology Fellows, Articles G